Not available
Quote | NovoCure Limited (NASDAQ:NVCR)
Last: | $12.23 |
---|---|
Change Percent: | -0.16% |
Open: | $12.36 |
Close: | $12.23 |
High: | $12.37 |
Low: | $11.88 |
Volume: | 1,008,570 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | NovoCure Limited (NASDAQ:NVCR)
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was...
Message Board Posts | NovoCure Limited (NASDAQ:NVCR)
Subject | By | Source | When |
---|---|---|---|
You go to $NWBO MB and thumsy up | KIPK | investorshub | 04/28/2023 3:58:51 PM |
LOL - THI HAT HAS NO CHNCE. THE | KIPK | investorshub | 04/28/2023 1:02:50 PM |
$NVCR has a great chance of retaking the | whosleftholdindabag | investorshub | 04/27/2023 9:21:22 PM |
Won't make a diff. SP will continue to | KIPK | investorshub | 04/27/2023 12:44:45 PM |
Results of LUNAR at ASCO. Also, nine other | jondoeuk | investorshub | 04/26/2023 6:00:33 PM |
News, Short Squeeze, Breakout and More Instantly...
NovoCure Limited Company Name:
NVCR Stock Symbol:
NASDAQ Market:
Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was...
Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, i...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three mo...